ATNF
180 Life Sciences Corp. [ATNF] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ATNF Stock Summary
Top 10 Correlated Stocks
ATNF
In the News
ATNF Financial details
Company Rating
-
Market Cap
1.84M
Income
-19.9M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.04
Forward P/E
-
PEG
0
P/S
-
P/B
-11.7
P/C
-
P/FCF
-0.19
Quick Ratio
0.58
Current Ratio
0.7
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-64.18
EPS next Y
-
EPS next Q
-
EPS this Y
-86.42%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-90.66%
-
-
-
-
SMA20
-20.24%
SMA50
204.55%
SMA100
230.86%
Inst Own
-
Inst Trans
-
ROA
-815%
ROE
-645%
ROC
-116.8%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.805-27.93
52W High
-90.96%
52W Low
+144%
RSI
41.12
Rel Volume
149.43
Avg Volume
93.39K
Volume
13.96M
Perf Week
-18.12%
Perf Month
-18.67%
Perf Quarter
128.04%
Perf Half Y
108.55%
-
-
-
-
Beta
0.437
-
-
Volatility
0.2%, 2.24%
Prev Close
5.63%
Price
2.44
Change
-2.4%
Company Profile
- Volume Average 93.39K
- Market Capitalization 1.84M
- Employee 4
- CEO Dr. James N. Woody M.D., Ph.D.
- Headquarters Palo Alto,CA,US
- IPO Date 2017-06-27
-
Website
https://180lifesciences.com 
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
